ALLO-647

Overview

ALLO-647 is an anti-CD52 monoclonal antibody which is designed to be part of the lymphodepletion regimen. ALLO-647 may reduce the likelihood of a patient’s immune system rejecting the engineered allogeneic T cells, and may create a window of persistence during which the engineered allogeneic T cells can actively target and destroy cancer cells.

SparkCures ID 359
Developed By Allogene Therapeutics
Generic Name ALLO-647
Treatment Classifications
Treatment Targets
  • CD52

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refrac...
View Trial
Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.